Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab vs platinum-based doublet in first-line PD-L1+ stage IV NSCLC
2015-001537-24Phase 3Terminated
- Sponsor
- Merck KGaA
- Start
- Oct 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avelumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoints: Progression-free survival in PD-L1 high subgroup and Overall survival in PD-L1 high subgroup. Started Oct 2015; status: terminated.
02
Drugs
avelumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-001537-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001537-24.